Table S1: Changes in PFT 3, 6 and 12 months after HSCT in the MSC and control groups.
Before HSCT 3 months 6 months 12 months
FEV1 pre‐BD (% pred)
MSC No MSC
89 23
89 17 95 22
87 17 93 22
90 15 91 19
89 21
FEV1 post‐BD (% pred)
MSC No MSC
88 23
87 13 94 22
87 15 92 23
92 16 90 20
89 24
FVC pre‐BD (% pred)
MSC No MSC
94 19
97 17 99 18
96 16 101 17
97 15 98 15
99 20
FVC post‐BD (% pred)
MSC No MSC
95 18
95 12 99 21
94 13 100 18
100 14 96 13
99 21
FEV1/FVC (%) MSC
No MSC
76 11
76 7 77 10
74 7 75 10
75 7 74 7
74 9
FEV1/FVC post BD (%) MSC No MSC
74 11
76 8 79 12
77 8 77 15
76 8 75 10
74 12 Corrected DLCO
(% pred)
MSC No MSC
73 25
74 22 69 21
75 16 75 24
74 17 75 23
70 15
Corrected KCO (% pred)
MSC No MSC
86 27
97 33 89 39
101 34 95 34
98 32 98 37
89 25
TLC (% pred)
MSC No MSC
94 14
94 19 91 13
92 13 94 15
92 16 96 12
94 22
RV (% pred) MSC
No MSC
93 36 99 46
104 45 99 34
97 39 96 41
99 46 99 48
FENO (ppb)
MSC No MSC
21 (13‐29) 15 (11‐23)
16 (10‐22) 13 (12‐19)
26 (17‐39) 16 (13‐30)
21 (13‐26) 19 (13‐35)
Results are expressed as mean SD except for FeNO value expressed as median (interquartile range). % pred: predicted percentage; FEV1:
forced expiratory volume in 1 second; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; KCO: gas transfer coefficient; TLC: total lung capacity; RV: residual volume; BD: bronchodilation. ; FeNO: exhaled nitric oxide.
Table S2: Univariate and multivariate Cox analysis of factors affecting the rate of pulmonary infections (left) and CMV reactivation (right) in the MSC and control groups combined (n=58)
Pulmonary infections
CMV reactivation
Factor HR (95% CI) P value
Factor HR (95% CI) P value
Univariate anlalysis
Age
Gender
Tobacco habits
Acute leukemia vs other diagnoses
Aspergillosis prior to HSCT
Female donor to male recipient
Number of CD34 cells transplanted
HLA mismatch and MSC
Secondary neutropenia
aGVHD CMV reactivation
1.00 (0.97‐1.04)
0.72 (0.30‐1.73)
1.15 (0.48‐2.76)
0.61 (0.25‐1.51)
2.73 (1.00‐7.44)
2.32 (0.89‐5.98)
0.89 (0.76‐1.04)
2.96 (1.15‐7.60)
1.35 (0.40‐4.56)
1.04 (0.42‐2.58)
1.12 (0.47‐2.66)
0.85
0.47
0.76
0.29
0.05
0.08
0.14
0.02
0.63
0.92
0.79
Univariate anlalysis
Age Gender
Tobacco habits
Acute leukemia vs other diagnoses
Aspergillosis prior to HSCT
Female donor to male recipient
Number of CD34 cells transplanted
HLA mismatch and MSC
Secondary neutropenia
aGVHD
Pulmonary infection
Donor CMV+ serostatus
Recipient CMV + serostatus
1.04 (1.00‐1.08)
1.26 (0.58‐2.75)
0.93 (0.40‐2.15)
1.00 (0.45‐2.21)
0.50 (0.12‐2.11)
2.12 (0.89‐5.06)
1.08 (0.95‐1.23)
0.96 (0.44‐2.09)
0.28 (0.04‐2.04)
1.74 (0.79‐3.83)
0.98 (0.43‐2.21)
2.28 (1.03‐5.03)
7.78 (2.31‐26.3)
0.07
0.57
0.87
1.00
0.35
0.09
0.23
0.92
0.21
0.17
0.96
0.04
0.0009
Multivariate analysis
Aspergillosis prior to HSCT
Female donor to male recipient
HLA mismatch and MSC
3.19 (1.08‐9.43)
2.29 (0.80‐6.56)
2.35 (0.88‐6.29)
0.04
0.13
0.09
Multivariate analysis
Age
Female donor to male recipient
Donor CMV+ serostatus
Recipient CMV+ serostatus
1.01 (0.97‐1.06)
2.25 (0.87‐5.81)
2.54 (1.10‐5.84)
7.56 (2.18‐26.23)
0.53
0.09
0.03
0.001
GVHD: graft versus host disease; CMV: cytomegalovirus; HR: hazard ratio